SCHEMBL5149331

SCHEMBL5149331

C[C@]12CCC3c4ccc(O)cc4CCC3C1CC[C@@H]2OC(=O)c1ccc(S(N)(=O)=O)nc1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 14/20 0.74
STS P08842 2/20 0.64
CA1 P00915 1/20 0.64
CA9 Q16790 1/20 0.64
KMT2A Q03164 4/20 0.64
LMNA P02545 4/20 0.64
MEN1 O00255 3/20 0.64
CYP3A4 P08684 3/20 0.64
ALOX15 P16050 3/20 0.64
MAPK1 P28482 2/20 0.64
BRCA1 P38398 1/20 0.64
RECQL P46063 1/20 0.64
MAPT P10636 4/20 0.61
TP53 P04637 2/20 0.61
ESR1 P03372 2/20 0.60
SMN1; SMN2 Q16637 2/20 0.58
HIF1A Q16665 1/20 0.58
PGR P06401 1/20 0.57
POLB P06746 1/20 0.57
ADORA3 P0DMS8 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5151136 0.88 CA2 (0.60) CA2STSCA1CA9KMT2A
SCHEMBL3866395 0.88 CA2 (0.77) CA2STSCA1CA9KMT2A
SCHEMBL5152447 0.85 CA2 (0.65) CA2STSCA1CA9KMT2A
SCHEMBL3868064 0.85 CA2 (0.66) CA2STSCA1CA9KMT2A
SCHEMBL5151164 0.85 CA2 (0.65) CA2STSCA1CA9KMT2A
SCHEMBL3871356 0.84 CA2 (0.73) CA2STSCA1CA9KMT2A
SCHEMBL9011258 0.82 LMNA (0.69) CA2STSCA1CA9KMT2A
SCHEMBL308659 0.82 LMNA (0.76) CA2STSCA1CA9KMT2A
SCHEMBL12180360 0.82 LMNA (0.76) CA2STSCA1CA9KMT2A
SCHEMBL26659960 0.82 LMNA (0.76) CA2STSCA1CA9KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070135399-A1 Heteroaromatic sulphonamide prodrugs BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2007-06-14 US claimed
US-20070135399-A1 Heteroaromatic sulphonamide prodrugs BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2007-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135399-A1 Heteroaromatic sulphonamide prodrugs SULT2A1, SULT1E1, SULT1A1 CA2 29/4885STS 4/4885CA1 129/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.